Muhdo Health Expands into Turkish Market with Exclusive Distribution Deal

In a significant move that could reshape the landscape of personalized health services in Turkey, Muhdo Health, a global frontrunner in DNA and Epigenetic consumer testing, has announced an exclusive distribution agreement with Rgentic Saglik Turizm ve Ticaret AS. This partnership aims to introduce Muhdo's genetic testing kits to the Turkish market, marking a pivotal expansion for the company's innovative health solutions.

The collaboration between Muhdo Health and Rgentic is set to make advanced genetic and epigenetic testing more accessible to Turkish consumers and healthcare providers. As part of this initiative, Muhdo Health will localize its services by translating its mobile app into Turkish, enabling local users to easily access and interpret their test results. Furthermore, the company's web-based Practitioner Portal will be available in Turkish, facilitating consultations in the native language and enhancing the ability of local clinics to provide personalized health insights.

To support this venture, Rgentic will launch a dedicated Turkish-language website, muhdo.com.tr, offering both DNA and Epigenetic tests directly to Turkish consumers and clinics. This strategic move is expected to significantly boost Muhdo's presence in Turkey's growing health and longevity sector.

The implications of this partnership extend beyond mere market expansion. By bringing advanced genetic and epigenetic testing to Turkey, Muhdo and Rgentic are poised to contribute to the advancement of personalized medicine and preventive healthcare in the region. This could lead to more targeted and effective health interventions, potentially improving overall health outcomes for the Turkish population.

Nathan Berkley, CEO of Muhdo Health, emphasized the strategic importance of this partnership, stating that it will increase the brand's exposure in Turkey and leverage Rgentic's robust commercial connections to propel the business forward. The collaboration is seen as a gateway to reaching a new audience in a territory known for its focus on health, wellbeing, and longevity.

Tekin Aldemir, Director of Rgentic, expressed enthusiasm about the partnership, highlighting the opportunity to provide their clients and partners with top-tier genetic and epigenetic testing solutions. Aldemir also hinted at the potential for future expansion beyond Turkey, leveraging Rgentic's existing network in neighboring territories.

This partnership comes at a time when personalized health solutions are gaining traction globally. The integration of genetic and epigenetic information into healthcare decision-making is increasingly recognized as a powerful tool for improving individual health outcomes and developing more effective prevention strategies. By bringing these advanced technologies to the Turkish market, Muhdo and Rgentic are positioning themselves at the forefront of this healthcare revolution in the region.

As the first company to offer a comprehensive internal wellness epigenetic profiling program directly to companies and consumers, Muhdo's entry into the Turkish market could spark increased interest in personalized health approaches. This move has the potential to inspire and support more people in Turkey to pursue healthier lifestyles based on their unique genetic profiles.

The success of this partnership could serve as a model for similar collaborations in other markets, potentially accelerating the global adoption of personalized genetic and epigenetic testing in healthcare. As Muhdo Health and Rgentic embark on this venture, the healthcare community will be watching closely to see how this integration of advanced genetic technologies impacts health outcomes and healthcare delivery in Turkey.